Strides Pharma Science received approval from the Drug Controller General of India to start clinical trials of the antiviral drug favipiravir to treat COVID-19, as reported in This is Money.
Favipiravir is manufactured under the brand name Avigan by a unit of Fujifilm and was approved for use as an anti-influenza drug in Japan in 2014.
Strides will do a bioequivalence study to compare the safety and efficacy of its drug with Avigan, a company spokesman said.
Strides' announcement comes after Glenmark Pharmaceuticals said last month it became the first drugmaker in India to get the nod to conduct favipiravir trials.
The Mumbai-based company has initiated late-stage clinical trials and expects study results by July or August.
To read more NewsPoints articles, click here.